- Roche's late stage pipeline 'so full,' CEO Schinecker not feeling pressure to add onRoche has 19 investigational medicines that could launch by 2030—and even if not all of them make it to market, the company is “well set-up for growth into the next decade,” CEO Thomas Schinecker s…BioSpace · 1d ago↗ source
- GSK’s $10.6B Nuvalent bet pays off early as FDA approves lung cancer drugJideytro is GSK’s first approved product for lung cancer. With its takeover of Nuvalent Bio last month and a deal with Hansoh Pharmaceutical in 2023, the pharma now has several other lung cancer as…BioSpace · 1d ago↗ source
- Lilly's triple agonist heads to regulators after two more Phase 3 obesity winsRetatrutide, the obesity candidate that has shown the most powerful weight loss in late-stage trials, will be filed for approval early next year, its developer Eli Lilly said Thursday. The filing…